AU2003271954A1 - Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases - Google Patents

Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases

Info

Publication number
AU2003271954A1
AU2003271954A1 AU2003271954A AU2003271954A AU2003271954A1 AU 2003271954 A1 AU2003271954 A1 AU 2003271954A1 AU 2003271954 A AU2003271954 A AU 2003271954A AU 2003271954 A AU2003271954 A AU 2003271954A AU 2003271954 A1 AU2003271954 A1 AU 2003271954A1
Authority
AU
Australia
Prior art keywords
expresion
cofilin
activity
treatment
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003271954A
Other versions
AU2003271954A8 (en
Inventor
Kevin B. Bacon
Herath Mudiyanselage Athula Chandrasiri Herath
Ningshu Liu
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2003271954A1 publication Critical patent/AU2003271954A1/en
Publication of AU2003271954A8 publication Critical patent/AU2003271954A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003271954A 2002-10-15 2003-10-15 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases Abandoned AU2003271954A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224014.1 2002-10-15
GBGB0224014.1A GB0224014D0 (en) 2002-10-15 2002-10-15 A protein involved in therapy
PCT/GB2003/004450 WO2004035092A2 (en) 2002-10-15 2003-10-15 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2003271954A1 true AU2003271954A1 (en) 2004-05-04
AU2003271954A8 AU2003271954A8 (en) 2004-05-04

Family

ID=9945978

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003271954A Abandoned AU2003271954A1 (en) 2002-10-15 2003-10-15 Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases

Country Status (3)

Country Link
AU (1) AU2003271954A1 (en)
GB (1) GB0224014D0 (en)
WO (1) WO2004035092A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207725A (en) * 2001-12-28 2004-03-23 Daiichi Suntory Biomedical Res Hematopoietic stem cell growth and / or differentiation promoters and / or hematopoietic progenitors
EP2195645B1 (en) * 2007-09-11 2014-05-07 Cancer Prevention And Cure, Ltd. Method for aiding in the diagnosis and therapy of asthma and lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
WO2002042451A2 (en) * 2000-11-27 2002-05-30 Cytokinetics Aspergillus fumigatus cofilin
FR2825928B1 (en) * 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan PHARMACEUTICAL COMPOSITION FOR DIAGNOSING, PREVENTING OR TREATING TUMOR PATHOLOGY, COMPRISING AN AGENT MODULATING POLYMERIZATION OF ACTIN

Also Published As

Publication number Publication date
GB0224014D0 (en) 2002-11-27
WO2004035092A2 (en) 2004-04-29
AU2003271954A8 (en) 2004-05-04
WO2004035092A3 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003282961A1 (en) Patient activity monitor
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
AU2002952993A0 (en) Therapeutic and diagnostic agents
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003272570A1 (en) Dressing for catheter assembly
AU2002333510A1 (en) Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
AU2003271954A1 (en) Use of an agent modulating cofilin expresion or activity for the treatment of inflammatory diseases
AU2003240545A1 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
AU2003288426A1 (en) Wound dressings containing an enzyme therapeutic agent
AU2003256447A1 (en) Treatment of autoimmune skin diseases
AU2003208776A1 (en) Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
AU1022501A (en) Use of compositions for the caring treatment of the skin
GB0201025D0 (en) The treatment of degenerative diseases
AU2003274649A1 (en) Diagnostic markers for therapeutic treatment
AU2003252187A1 (en) Topical composition for the treatment of inflammatory conditions of the skin
AU3827199A (en) Use of antioxidants for the treatment of inflammatory skin diseases
AU2002344959A1 (en) Use of fasl for the treatment of neurodegenerative diseases
AU2003295504A1 (en) Development of therapeutics for the treatment of endotoxin-mediated diseases
AU2003232844A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase